Siedner, Mark J. http://orcid.org/0000-0003-3506-842X
Moorhouse, Michelle A. http://orcid.org/0000-0002-8410-3247
Simmons, Bryony http://orcid.org/0000-0002-3207-9935
de Oliveira, Tulio
Lessells, Richard http://orcid.org/0000-0003-0926-710X
Giandhari, Jennifer
Kemp, Stephen A.
Chimukangara, Benjamin
Akpomiemie, Godspower
Serenata, Celicia M. http://orcid.org/0000-0001-7921-0948
Venter, Willem D. F.
Hill, Andrew
Gupta, Ravindra K. http://orcid.org/0000-0001-9751-1808
Article History
Received: 19 July 2020
Accepted: 28 October 2020
First Online: 1 December 2020
Competing interests
: R.K.G. has received ad hoc consulting fees from Gilead, ViiV and UMOVIS Lab. W.D.F.V. received drug donations from ViiV Healthcare and Gilead Sciences for investigator-led clinical studies, including ADVANCE. In addition, he receives honoraria for talks and board membership for: Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, J&J. M.A.M. received drug donations from ViiV Healthcare and Gilead Sciences for investigator-led clinical studies, including ADVANCE. In addition, she received honoraria for talks and board membership for: Gilead, ViiV, Mylan, Aspen, AbbVie, Johnson & Johnson, Sanofi, Pfizer and Southern African HIV Clinicians Society. She also received meeting/conference sponsorship from Johnson and Johnson, BD, Gilead, Merck, Cipla, Mylan and Canopy Growth. No other authors have any conflict of interest.